Analysis

Originally developed by Metabolic Pharmaceuticals as a fat-mass-targeting analogue of the lipolytic C-terminal fragment of hGH. The 12-week Phase 2b trial (Heffernan 2001 mechanism, full Phase 2b reported 2007) failed the obesity primary endpoint. Subsequent positioning as a research peptide rests on the mechanism story rather than positive clinical efficacy.

AOD-9604 is a 16-amino-acid synthetic fragment of human growth hormone, taken from the C-terminal lipolytic region (residues 176–191). Metabolic Pharmaceuticals developed it through the early 2000s as an oral anti-obesity agent. The hypothesis was clean: isolate the lipolytic fragment of hGH from the IGF-1-mediated anabolic effects, deliver fat-mass reduction without growth-related side-effect risk. Phase 1 tolerability and Phase 2 mechanism studies supported the concept. The 12-week Phase 2b in obese adults then did not show the weight-loss effect size required to advance to Phase 3, and the development program was discontinued in 2007. Methodology v1.2 scores AOD-9604 5.1. The mechanism case is real, but the human evidence is the failed Phase 2b plus a handful of small pilots in repositioning indications (osteoarthritis, cartilage repair) where effect sizes have been small and replication limited. The peptide's continued circulation in the research-channel market rests on the mechanism narrative, not on positive trial data. The gap between the marketing framing and the published trial outcome is one of the more actively-misleading patterns we cover in the database.